Related Experiment Videos
Inflammatory processes in Alzheimer's disease.
Edith G McGeer1, Patrick L McGeer
1Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada V6T 1Z3. mcgeer@interchange.ubc.ca
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|August 19, 2003
Summary
Neuroinflammation, marked by activated immune cells and inflammatory molecules in the brain, is prominent in Alzheimer's disease (AD). Anti-inflammatory drugs may offer a therapeutic strategy for managing AD progression.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Neuroinflammation is a key feature in neurodegenerative disorders, notably Alzheimer's disease (AD).
- Affected brain regions in AD show increased activated microglia, astrocytes, and T-cells.
- Biochemical changes include heightened inflammation and free radical damage markers.
Purpose of the Study:
- To investigate the role of neuroinflammation in Alzheimer's disease.
- To explore the potential of anti-inflammatory agents in AD treatment.
Main Methods:
- Histopathological examination of affected brain tissue.
- Biochemical analysis of inflammatory markers.
- Review of epidemiological data on anti-inflammatory drug use.
Main Results:
- Significant accumulation of activated microglia and astrocytes observed in AD brain tissue.
- Presence of inflammatory molecules, complement proteins, acute phase reactants, and cytokines.
- Epidemiological data suggest a protective effect of anti-inflammatory agents in AD.
Conclusions:
- Neuroinflammation is a critical component of Alzheimer's disease pathology.
- The findings support the potential therapeutic value of anti-inflammatory agents for AD.